Organon and Pharmacopeia Enter Into Alliance
This is old news from back in Feb but given the recent announcement of acquisition by Schering-Plough I thought it worth commenting on.
It will be interesting to see what comes out of this agreement now that Schering-Plough will be making the calls once the merger is approved later this year. I don’t know that Schering-Ploug will want to continue with Pharmacopeia but I could be mistaken. I certainly don’t think SP wants to co-develop and co-commercialize future drugs with Pharmacopeia.
Some times agreements such as these can be impediments to acquisitions but I personally think the deal/agreement route is better than the straight acquisition. However these agreements can also mean that the smaller entity can end up being a target that it might not otherwise be due to the terms of the agreement. Icos is still the best example of that. It made more sense monetarily for Lilly to just purchase Icos than to continue to pay royalties under the terms of their agreement.
Technorati Tags: Organon Biosciences, Pharmacopeia, Schering-Plough
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
